Benefits OverviewEnrollment & ParticipationEngagement & PersistenceClinical OutcomesClinical PathwayMedical UtilizationProgram PerformanceMember ExperienceEngagement & Outcomes
Benefits OverviewEnrollment & ParticipationEngagement & PersistenceClinical OutcomesClinical PathwayMedical UtilizationProgram PerformanceMember ExperienceEngagement & Outcomes
Benefits Intelligence · Benefits Director
Program Performance
Member participation, persistence, program fees, and outcome-based payment components.
Sample data
Program fee
$10.80M
$5,400 / member
ObservedFee at risk
$2.70M
25% on outcomes
Observed6-month persistence
79%
remain on treatment
ObservedActive members
1,326
currently engaged
ObservedPerformance-based fee adjustment
Outcome targets
Total targets5
Targets met4
Targets unmet1
Total program fee$10.80M
Fee at risk$2.70M25%
Adjustment−$540K1 unmet
Adjusted fee$10.26M95% of original
Target performance
Target 1
Met
Target 2
Met
Target 3
Met
Target 4
Met
Target 5
Unmet
Whether the adjustment is a credit, refund or withheld payment depends on the agreement.
Member participation & persistence
ObservedEnrolled
2,000
total enrolled
ObservedActive at 90 days
1,524
91% of started
ObservedActive at 6 months
1,326
79% of started
ObservedMeasurable improvement
1,009
paired measurements
MeasuredEmployer benefits investment
Program fee (annual)$10.80M$5,400 × 2,000 members
Fee at risk$2.70M25% contingent on outcomes
Adjusted fee (after targets)$10.26M95% of original
GLP-1 drug spending$8.11Mseparate from program fee
Total benefits investment$18.37Mfee + therapy
Program fees and GLP-1 drug spending are separate components of the total employer investment. Fee at risk ties a portion of the fee to outcome target achievement.
Engagement indicators
Meaningful actions / week
2.8
per active member
ObservedTimely follow-up
80%
same-day response
ObservedRefill adherence
91%
medication persistence
ObservedEmployee Privacy Protected by Design
Employer reporting is designed to present aggregate workforce and health-program insights without exposing individual clinical records. Small-group reporting restrictions help reduce the risk of employee identification.
Sample dataPrivacy-restricted reporting
Aggregated information is not described as HIPAA-de-identified unless applicable de-identification requirements have been satisfied and verified.